Continuity and presence of side effects of continuous subcutaneous apomorphine infusion and levodopa-carbidopa intestinal gel infusion in advanced Parkinson’s disease, in a movement disorder unit in Spain
Objective: To determine the number of patients that maintain infusion therapies (continuous subcutaneous apomorphine infusion (CSAI) and levodopa-carbidopa intestinal gel (LCIG)) as treatment for advanced…Continuous subcutaneous foslevodopa/foscarbidopa: final results from a phase 3, open-label study
Objective: Evaluate safety and efficacy of foslevodopa/foscarbidopa (LDP/CDP) for patients with Parkinson’s disease (PD) in a 52-week, phase 3 study. Background: As PD progresses, patients…Efficacy and safety of adjunctive oral therapy in Parkinson’s disease with motor complications: a systematic review and network meta-analysis
Objective: To review the evidence and compare the efficacy and safety of catechol-O-methyltransferase inhibitors (COMT-Is), dopamine agonists (DAs) and monoamine-oxidase B inhibitors (MAOB-Is) as adjunctive…Beta LFP Power Change After Levodopa Intake in Parkinson’s Disease Patients with Chronic Sensing-Enabled DBS Systems
Objective: To study the relationship between oscillatory beta activity in the subthalamic nucleus (STN) and the intake of dopaminergic medication in a group of Parkinson’s…Continuous subcutaneous levodopa/carbidopa infusion with ND0612 for Parkinson’s disease: Three-year data from the open-label BeyoND study
Objective: To evaluate three-year outcomes from the ND0612 BeyoND study. Background: Investigational ND0612 is in development as a 24-hour continuous, subcutaneous infusion of liquid levodopa/carbidopa…Basal ganglia shape in de novo Parkinson’s disease patients can predict the onset of Levodopa Induced Dyskinesias
Objective: In the current study, we aimed to examine structural MRI data from a large sample of de novo PD patients and to identify potential…The Journey Of Levodopa Treatment in Parkinson’s disease
Objective: This study aims to relook the journey of levodopa in the treatment of Parkinson’s disease. Background: Levodopa has been used in the treatment of…Levodopa-carbidopa intestinal gel (LCIG) as an add-on therapy to deep brain stimulation (DBS) for managing progressive symptoms of advanced idiopathic Parkinson’s disease during the COVID-19 pandemic: Case Report
Objective: To report the use of levodopa-carbidopa intestinal gel (LCIG) as an additional therapy for the treatment of motor fluctuations in a patient with advanced…GLA-associated early-onset Parkinson’s disease: the mimicry between Fabry disease and parkinsonisms
Objective: To characterize an early-onset Parkinson’s disease (EOPD) patient with atypical clinical phenotype. Background: Genome sequencing is allowing new Parkinsonian Syndromes (PS)-associated genes identification. However,…Effects of Parkinson’s disease and freezing of gait on the kinematic and kinetic gait parameters
Objective: This study aims to evaluate the effects of Parkinson's disease and freezing of gait (FoG) on the kinematic and kinetic gait parameters, both in…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 57
- Next Page »